Effects of HIV protease, nucleoside/non-nucleoside reverse transcriptase inhibitors on Bax, Bcl-2 and apoptosis in two cervical cell lines

Biomedicine and Pharmacotherapy

Volumn 68, Issue 2, 2014, Pages 241-251

  Adefolaju, Gbenga Anthony ^a   Theron, Kathrine Elizabeth ^b   Hosie, Margot Jill ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

Antiretroviral drugs; Apoptosis; Bax Bcl 2

Indexed keywords

CAMPTOTHECIN; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; REGULATOR GENE; UTERINE CERVIX CANCER;

ANTIRETROVIRAL DRUGS; APOPTOSIS; BAX/BCL-2;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HIV PROTEASE INHIBITORS; HUMANS; NUCLEOSIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE INHIBITORS; UTERINE CERVICAL NEOPLASMS;

EID: 84897068703     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.08.007     Document Type: Article

References (33)

1. Nachega J.B., Stein D.M., Lehman D.A., Hlatshwayo D., Mothopeng R., Chaisson R.E., et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004, 20:1053-1056.
2. Sikora M.J., Rae J.M., Johnson M.D., Desta Z. Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. HIV Med 2010, 11:603-607.
3. Blas-Garcia A., Apostolova N., Ballesteros D., Monleon D., Morales J.M., Rocha M., et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010, 52:115-125.
4. Olivero O.A., Anderson L.M., Diwan B.A., Haines D.C., Harbaugh S.W., Moskal T.J., et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997, 89:1602-1608.
5. Blanche S., Tardieu M., Rustin P., Slama A., Barret B., Firtion G., et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354:1084-1089.
6. IARC IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization 2000, 1-521. IARC Scientific Publications, Lyon, France.
7. Torres S.M., Walker D.M., Carter M.M., Cook D.L., McCash C.L., Cordova E.M., et al. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen 2007, 48:224-238.
8. Barbaro G., Barbarini G. HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep 2007, 17:1121-1126.
9. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009, 4:52-56.
10. Hessol N.A., Pipkin S., Schwarcz S., Cress R.D., Bacchetti P., Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007, 165:1143-1153.
11. Nguyen M.L., Farrell K.J., Gunthel C.J. Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep 2010, 12:46-55.
12. Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009, 27:884-890.
13. Olivero O.A., Tejera A.M., Fernandez J.J., Taylor B.J., Das S., Divi R.L., et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 2005, 20:139-146.
14. Gills J.J., Lopiccolo J., Tsurutani J., Shoemaker R.H., Best C.J., Abu-Asab M.S., et al. Nelfinavir. A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13:5183-5194.
15. Badley A.D. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 2005, 12(Suppl.1):924-931.
16. Fiebig A.A., Zhu W., Hollerbach C., Leber B., Andrews D.W. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 2006, 6:213.
17. Rosse T., Olivier R., Monney L., Rager M., Conus S., Fellay I., et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998, 391:496-499.
18. Rizza S.A., Badley A.D. HIV protease inhibitors impact on apoptosis. Med Chem 2008, 4:75-79.
19. Borenfreund E., Puerner J.A. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 1985, 24:119-124.
20. Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007, 8:R19.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
22. Phenix B.N., Lum J.J., Nie Z., Sanchez-Dardon J., Badley A.D. Anti-apoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001, 98:1078-1085.
23. Mironova E.V., Evstratova A.A., Antonov S.M. A fluorescence vital assay for the recognition and quantification of excitotoxic cell death by necrosis and apoptosis using confocal microscopy on neurons in culture. J Neurosci Methods 2007, 163:1-8.
24. Ribble D., Goldstein N.B., Norris D.A., Shellman Y.G. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5:12.
25. Yang S., Liu M., Liang N., Zhao Q., Zhang Y., Xue W., et al. Discovery and antitumor activities of constituents from Cyrtomium fortumei (J.) Smith rhizomes. Chem Cent J 2013, 7:24. 153X-7-24.
26. Canete M., Juarranz A., Lopez-Nieva P., Alonso-Torcal C., Villanueva A., Stockert J.C. Fixation and permanent mounting of fluorescent probes after vital labelling of cultured cells. Acta Histochem 2001, 103:117-126.
27. Vlahakis S.R., Bennett S.A., Whitehead S.N., Badley A.D. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 2007, 12:969-977.
28. Renvoize C., Biola A., Pallardy M., Breard J. Apoptosis: identification of dying cells. Cell Biol Toxicol 1998, 14:111-120.
29. Apostolova N., Gomez-Sucerquia L.J., Moran A., Alvarez A., Blas-Garcia A., Esplugues J.V. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 2010, 160:2069-2084.
30. Gomez-Sucerquia L.J., Blas-Garcia A., Marti-Cabrera M., Esplugues J.V., Apostolova N. Profile of stress and toxicity gene expression in human hepatic cells treated with efavirenz. Antiviral Res 2012, 94:232-241.
31. Dal Maso L., Polesel J., Serraino D., Lise M., Piselli P., Falcini F., et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009, 100:840-847.
32. Heard I. Prevention of cervical cancer in women with HIV. Curr. Opin. HIV AIDS 2009, 4:68-73.
33. Bratcher L.F., Sahasrabuddhe V.V. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 2010, 5:8. 9378-5-8.